Abstract
Glycoprotein IIb/IIIa inhibitors reduce ischemic complications during percutaneous coronary intervention (PCI). However, in the partially industry-supported ISAR-REACT trial (Journal Watch Cardiology Feb 27 2004), abciximab did not add benefit to clopidogrel pretreatment in low- and intermediate-risk patients undergoing elective PCI. What about in high-risk …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
